<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527174</url>
  </required_header>
  <id_info>
    <org_study_id>1230-37</org_study_id>
    <nct_id>NCT02527174</nct_id>
  </id_info>
  <brief_title>A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia</brief_title>
  <acronym>VIAC</acronym>
  <official_title>A Phase I Study of Volasertib Combined With Standard Induction Chemotherapy for Previously Untreated Patients With Acute Myeloid Leukemia (VIAC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I clinical trial to determine the maximum tolerated dose (MTD) of the&#xD;
      polo-like kinase-1 inhibitor volasertib which can be safely combined with idarubicin plus&#xD;
      cytarabine induction chemotherapy for previously untreated patients with acute myeloid&#xD;
      leukemia. (AML).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main inclusion criteria:&#xD;
&#xD;
        1. AML, any subtype except acute promyelocytic leukemia (APL)&#xD;
&#xD;
        2. At least one of the following features:&#xD;
&#xD;
           i. Age 18-75 with adverse risk cytogenetics ii. Age 18-75 with antecedent&#xD;
           myelodysplastic syndrome (MDS) or myeloproliferative disorder (MPD), or therapy-related&#xD;
           AML iii. Age 60-75, regardless of risk category&#xD;
&#xD;
        3. No prior therapy for AML other than hydroxyurea&#xD;
&#xD;
        4. Judged by treating physician to be medically fit for induction chemotherapy&#xD;
&#xD;
        5. Eastern Cooperative Oncology Group (ECOG) performance status score 0-2&#xD;
&#xD;
        6. Normal left ventricular ejection fraction&#xD;
&#xD;
      Subjects will receive induction chemotherapy consisting of idarubicin 12 mg/m2 on Days 1-3&#xD;
      plus cytarabine 200 mg/m2 (age 18-59) or 100 mg/m2 (age 60-75) as a continuous IV infusion x&#xD;
      7 days. Volasertib will be administered on day 4 in a dose-escalation schedule, using a&#xD;
      standard 3+3 dose escalation design, over 3 dose levels. Once the MTD has been determined, an&#xD;
      additional dose expansion cohort will be accrued.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Volasertib no longer available&#xD;
  </why_stopped>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>Participants will be followed for duration of induction cycle (expected time 28-35 days) for toxicity.</time_frame>
    <description>Non-hematologic toxicities will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Hematologic toxicities will be assessed by determining number of days to neutrophil (ANC) recovery to &gt;0.5 x10(9)/L or platelet recovery to &gt;20 x10(9)/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>Participants will be followed for duration of induction cycle (expected time 28-35 days) for DLT assessment.</time_frame>
    <description>DLT is defined as grade 3-4 non-hematologic toxicity (except grade 3 nausea, vomiting, mucositis or creatinine elevation due to tumor lysis syndrome, and grade 3-4 neutropenic infections and electrolyte abnormalities) using CTCAE version 4.0.Hematologic DLT is defined as ANC recovery to &gt;0.5 x10(9)/L or platelet recovery to &gt;20 x10(9)/L of &gt; 42 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>Determined after completion of dose-escalation phase of study, which will take approx. 12-15 months.</time_frame>
    <description>MTD is defined as maximum dose of volasertib associated with &lt; 2/6 DLTs at a given dose level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate of regimen</measure>
    <time_frame>Responses will be determined at hematologic recovery (Day 28 or greater, up to Day 60).</time_frame>
    <description>Complete response (CR) defined as &lt;5% marrow blasts with ANC &gt; 1.0 x10(9)/L and platelets &gt;100 x 10(9)/L, with no extramedullary disease. CRi defined as same, but ANC &lt;1.0 and/or platelets &lt;100.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Leukemia, Monocytic, Acute</condition>
  <condition>Leukemia, Myelomonocytic, Acute</condition>
  <condition>Leukemia, Erythroblastic, Acute</condition>
  <condition>Leukemia, Megakaryoblastic, Acute</condition>
  <arm_group>
    <arm_group_label>Study treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive volasertib combined with idarubicin plus cytarabine in a 3+7 schedule as induction chemotherapy. Volasertib dose will be given on day 4 in a dose escalation schedule over 3 dose levels (140 mg/m2, 170 mg/m2, 200 mg/m2) in successive cohorts.&#xD;
Non-hematologic toxicity will be determined using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 criteria for adverse events. Hematologic toxicity will be determined by days to absolute neutrophil count (ANC) and platelet recovery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Volasertib</intervention_name>
    <description>Addition of single dose of volasertib intravenously (IV) on Day 4 of treatment protocol.</description>
    <arm_group_label>Study treatment arm</arm_group_label>
    <other_name>BI 6727</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>Given IV daily on Days 1-3 of treatment protocol.</description>
    <arm_group_label>Study treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV daily as 24-hour continuous infusion on Day 1-7 of treatment protocol.</description>
    <arm_group_label>Study treatment arm</arm_group_label>
    <other_name>Ara-C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. AML, any World Health Organization (WHO) subtype except APL, either de novo or&#xD;
             secondary; extramedullary AML (i.e. granulocytic sarcoma) is permitted.&#xD;
&#xD;
          2. At least one of the following features:&#xD;
&#xD;
               -  Age 18-75 with adverse risk cytogenetics, including:&#xD;
&#xD;
                    -  Complete or partial deletion of chromosome 5 or 7&#xD;
&#xD;
                    -  Complex karyotype, defined as &gt; 3 abnormalities, excluding t(15;17). t(8;21)&#xD;
                       or inv(16) or variant&#xD;
&#xD;
                    -  11q23 abnormality&#xD;
&#xD;
                    -  Inv(3)(q21;q26) or variant&#xD;
&#xD;
                    -  t(6;9)&#xD;
&#xD;
                    -  abn(17p)&#xD;
&#xD;
               -  Age 18-75 with secondary AML, defined as arising from an antecedent&#xD;
                  myelodysplastic syndrome (MDS) or myeloproliferative disorder (MPD), or&#xD;
                  therapy-related AML&#xD;
&#xD;
               -  Age 60-75, regardless of risk category&#xD;
&#xD;
          3. No prior therapy for AML other than hydroxyurea (allowed for up to 28 days). Prior&#xD;
             therapy for MDS, MPD or other malignancy is allowed.&#xD;
&#xD;
          4. Judged by treating physician to be medically fit for induction chemotherapy&#xD;
&#xD;
          5. ECOG performance status score 0-2.&#xD;
&#xD;
          6. Left ventricular ejection fraction (LVEF) within normal limits, by myocardial&#xD;
             multigated scan (MUGA) or echocardiogram.&#xD;
&#xD;
          7. Signed and dated written informed consent prior to admission&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior anthracycline exposure equivalent to &gt; 300 mg/m2 doxorubicin.&#xD;
&#xD;
          2. Prior chemotherapy or radiotherapy within previous four weeks except for hydroxyurea.&#xD;
&#xD;
          3. Prior treatment with volasertib or any other Polo-like kinase inhibitor&#xD;
&#xD;
          4. Known hypersensitivity to the trial drug&#xD;
&#xD;
          5. Serum creatinine &gt; 1.5 times (1.5x) upper limit of normal (ULN) or creatinine&#xD;
             clearance (CLcr) &lt; 30 ml/min (estimated creatinine clearance by the Cockcroft-Gault&#xD;
             (C-G) equation&#xD;
&#xD;
          6. Serum bilirubin &gt; 1.5x ULN, or aspartate aminotransferase (AST) or alanine&#xD;
             aminotransferase (ALT) &gt; 3x ULN&#xD;
&#xD;
          7. Persistence of clinically relevant therapy related toxicity from previous anti-cancer&#xD;
             therapy&#xD;
&#xD;
          8. Active central nervous system leukemia (no lumbar puncture required; clinical&#xD;
             judgement is sufficient)&#xD;
&#xD;
          9. Treatment with other investigational drugs or treatment in another clinical trial&#xD;
             within the past 4 weeks before start of therapy or concomitantly with the trial&#xD;
&#xD;
         10. Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina,&#xD;
             history of infarction within the past 12 months prior to start of study treatment,&#xD;
             congestive heart failure (&gt; New York Heart Association-II), serious cardiac&#xD;
             arrhythmia, pericardial effusion)&#xD;
&#xD;
         11. QTcF prolongation &gt; 470 ms or QT prolongation deemed clinically relevant by the&#xD;
             investigator (e.g., congenital long QT syndrome).The QTcF will be calculated as the&#xD;
             mean of the 3 ECGs taken at screening.&#xD;
&#xD;
         12. Other concurrent malignancy requiring active therapy (except hormonal therapy for&#xD;
             prostate or breast cancer).&#xD;
&#xD;
         13. Severe uncontrolled infection. Controlled infection on antibiotics is permitted.&#xD;
&#xD;
         14. Active or chronic hepatitis C and/or B infection&#xD;
&#xD;
         15. Known HIV infection&#xD;
&#xD;
         16. Serious illness or concomitant non-oncological disease such as neurologic,&#xD;
             psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or&#xD;
             laboratory abnormality that may increase the risk associated with study participation&#xD;
             or study drug administration and in the judgment of the investigator would make the&#xD;
             patient inappropriate for entry into the study.&#xD;
&#xD;
         17. Patients who are sexually active and unwilling to use a medically acceptable method of&#xD;
             contraception (e.g. such as implants, injectables, combined oral contraceptives, some&#xD;
             intrauterine devices or vasectomized partner for participating females, condoms for&#xD;
             participating males) during the trial and for at least six months after end of active&#xD;
             therapy on study.&#xD;
&#xD;
         18. Pregnancy or breast feeding, female patients must have a negative pregnancy test prior&#xD;
             to commencing study treatment.&#xD;
&#xD;
         19. Psychological, familial or sociological factors potentially hampering compliance with&#xD;
             the study protocol and follow-up schedule&#xD;
&#xD;
         20. Known or suspected active alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Brandwein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Joseph Brandwein</investigator_full_name>
    <investigator_title>Director, Division of Hematology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Monocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized data will be made available to Boehringer-Ingelheim.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

